Tame: An R package for identifying clusters of medication use based on dose, timing and type of medication

Anna Laksafoss[1*], Jan Wohlfahrt[2], Anders Hviid[1,3]

[1] Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.

[2] Danish Cancer Institute, Cancer Epidemiology and Surveillance, Strandboulevarden 49, 2100 Copenhagen, Denmark

[3] Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark

*Corresponding Author: Anna Laksafoss

Figures: 2

Supplementary Materials: 8 supplementary sections, including 7 tables and 2 figures

Word Count – Abstract: 270 words

Word Count – Main: 3502 words

ABSTRACT

Objective

Simplified exposure classifications such as *ever exposed* versus *never exposed* are commonly used in pharmacoepidemiology. However, this simplification may hide complex use patterns of relevance to researchers. Here we introduce `tame`, an R package for classifying medication use patterns, capturing complexities such as timing, dose, and concurrent medication use in real-world data.

Methods

`tame` identifies complex clusters of medication use based on similarities in the Anatomical Therapeutic Chemical (ATC) Classification System, medication timing, and medication dose. Agglomerative hierarchical clustering is performed with a novel distance measure, which can be customized to context and research questions. The package provides methods for clustering medication data, analysing and illustrating the clusters, and employing these clusters to new data in a similar format.

Results

In a national Danish cohort study, `tame` was utilized to investigate complex trends of antidepressant use before- and during pregnancy, showcasing its ability to identify nuanced medication patterns.

`tame` is available on the Comprehensive R Archive Network at [https://CRAN.R-project.org/package=tame] under an MIT license. A development version of the package is public on GitHub at [https://github.com/Laksafoss/tame].

Conclusion

`tame` provides a comprehensive approach to medication use classification. Its application extends beyond individual medication analysis, enabling the detection of complex medication interactions and enhancing our understanding of medication usage outside clinical trial settings. Clustering real-

world medication data offers an automated method for detecting potential safety signals or adverse drug interactions, and can enhancing our understanding of diverse medication usage outside clinical trial settings. In addition, these patterns can be leveraged for stratification of treatment effect estimates in epidemiological studies.

Key Words

Polypharmacy, medication trajectories, unsupervised machine learning, clustering, R package, epidemiology

INTRODUCTION

Developments in the field of machine learning, improvements in computing power, and the increasing richness of data now make it feasible to conduct more nuanced analyses of medication patterns. A number of recent studies have explored data-driven approaches to exposure classification. For example, methods such as longitudinal k-means and latent class analysis have been applied to longitudinal medication data to classify exposure trajectories (1,2,3,4), and these methods have been implemented in software such as the R-packages `kml` (5,6) and `lcmm` (7). However, these methods focus exclusively on drug exposure timing and are thus not suitable to explore the detailed, complex interactions between multiple medications or medication classes. Few developments have been made to approaches which learn from both exposure timing and the chemical and therapeutic characteristics of the medication(s) used (8), which are very important for studying drug safety. To the authors' knowledge, no publicly available software that learns from this combined information to identify real-world prescription drug use patterns exists.

In this paper, we present a Hierarchical Cluster Analysis (HCA) method that utilises exposure timing, dose intensity, and type of medication to classify medication use. HCA is a general and highly adaptable approach to cluster analysis that allows for the clustering of any data, provided that the user can specify the distance between any pair of observations. We developed a distance measure specifically designed for the clustering of patterns of medication use by Anatomical Therapeutic Clustering (ATC) code, timing, and dose. The distance measure allows for flexible specification of the component parts – ATC code, timing and dose – and their relative importance. The method avoids unwanted data reduction or oversimplification of information by defining the distance measure on the person- and medication-specific level. Here, we apply the method to a Danish nationwide cohort of pregnancies with at least one antidepressant used 0-24 weeks prior to pregnancy onset in order to map Danish mothers' use of antidepressants leading up to- and during pregnancy.

IMPLEMENTATION

`tame` is implemented in R (R Development Core Team 2022) as a package and requires the following R packages: `dplyr` (≥1.1.0), `fuzzyjoin`, `magrittr`, `purrr`, `Rfast`, `rlang`, `stats`, `stringr`, `tibble`, `tidyr`, `tidyselect`, `Rcpp` (≥ 1.0.8). A development version is also available on GitHub [https://github.com/Laksafoss/tame] and collaborators are welcome to fork or make pull requests. The `tame` package provides methods for clustering medication data by ATC codes, dose and timing, analysing and illustrating these clusters, and employing these learned clusters to new data in a similar format. These central functionalities are implemented in the functions `medic()`, `summary()`, and `employ()`, along with a few supporting functions. The package also includes a simulated dataset for demonstrating the code.

Hierarchical Clustering Analysis

Our medication clustering method, `medic()`, is an agglomerative hierarchical cluster analysis (HCA) with a bespoke distance measure. The distance measure specifies the distance between any pair of observations, and a linkage criterion specifies the distance between sets of observations.

Our contribution lies in the development and implementation of a novel distance measure between two individual-level medication use information involving multiple types of medication information. This distance measure is a composite measure of a dose intensity, timing of medication and an ATC-based distance measure weighted together.

Difference in two individual-level medication profiles by dose intensity and timing of medication are measured by a dose trajectory distance measure. This distance measure compares the medication dose at each timepoint in the study and summarizes across time using the Minkowski distance. The mathematics behind the method are available in S1, and a mathematical glossary is available in S2

The ATC distance measure compares two medications by considering the levels of the medications ATC code. The distance between two medications is found by identifying the deepest ATC code level that is shared between the two medications. For example, sertraline *N06AB06* and clomipramine *N06AA04* are both antidepressants (*N06A*) and are identical at ATC level 3, but sertraline *N06AB06* and oxycodone *N02AA05* are only identical at ATC level 1, where they share the nervous system main group (*N*). Thus, the distance between sertraline *N06AB06* and clomipramine *N06AA04* is smaller than the distance between sertraline *N06AB06* and oxycodone *N02AA05*. Note that if two medications have the same ATC codes, their distance is 0, and they are considered to be the same medication under this distance measure.

A wide range of parameters allow for the tuning of the dose trajectory distance measure, the ATC distance measure, and their relative importance. This is an important issue, that can be complex, thus, detailed explanations and discussions of these tuning parameters and more can be found in S3.

This method, as many other clustering methods, is computationally intensive. For a technical discussion on these aspects of the implementation, see S4.

`medic()`: Identifying clusters

The `medic()` function is the central power house of the `tame` package. This function computes the distances between all pairs of individuals, runs the hierarchical clustering algorithm, and returns the clusters.

The function requires that the user provides a dataset where each row encodes personal medication patterns of each medication. Thus, a person exposed to 3 medications has 3 rows in the data. In S5 examples of how data might be structured can be found. Columns in this dataset naming the person identification variable, the medication ATC code variable, and, if available, one or more numerical variables encoding dose and/or exposure trajectory. The user specifies the desired number(s) of

clusters with the function input `k`. Moreover, a number of function parameters can be used to tune the distance. A full discussion of these tuning parameters can be found in S3.

`summary()`: Summarizing clusters

A wide range of cluster summarisation tools are implemented in the `summary()` function. The list of summarisation approaches is given in the code documentation (9), and the latest version at time of publication can be found in S7. As an example, Figure 1 has been made using these summary tools.

Figure 1. Characteristics of medication use clusters in a cohort of 33,655 Danish pregnant women with at least 1 antidepressant prescription within the six months before pregnancy. Columns display clusterwise characteristics. The first row illustrates the number of antidepressants used, the second row illustrates the 5 most prevalent antidepressant ATC codes, and the remaining 4 rows illustrate the average antidepressant exposure timing by anti-depressive type.

`employ()`: Applying Clusters to New Data

An important functionality of the package is the `employ()` function, which takes an existing constellation and a new dataset and uses this particular constellation on the new data. Each new individual is assigned to the closest existing cluster. This functionality enables the learning of the constellation on a sub-cohort such that this constellation can be applied to the entire cohort. This is especially advantageous for saving computational time by clustering on a representative sub-cohort and then generalizing, or when working with a distinct sub-cohort, which should guide the learning of medication features (e.g., persons with a specific diagnosis or persons exposed to a specific interest medication). Moreover, this functionality enables easy sharing of learned clusters across studies and countries.

140

141 **Installation**

142 The tame package is available on *The Comprehensive R Archive Network* (CRAN), and may be installed
143 by running `install.packages("tame")` in R ≥4.2. Additionally, development versions may be
144 available on github at https://github.com/Laksafoss/tame.

145

146 USE

147 To demonstrate the use and utility of `tame`, we apply the methodology to the medication use
148 immediately before- and during pregnancy using a cohort of Danish women with a history of
149 antidepressant use before pregnancy. We investigate how these medications are used in practice, and
150 how use is related to redeeming psycholeptics in the first year after pregnancy. Please note that this
151 study primarily serves as an example of how to use the package.

152 **Characterizing Antidepressant Use Before and During Pregnancy**

153 We identified all live-born singleton births with a gestational age of at least 36 weeks between 1997
154 and 2016 in the Danish Medical Birth Registry (10). Using the Danish National Prescription Registry,
155 the cohort was restricted to women who redeemed at least one antidepressant within the six months
156 before pregnancy. To conduct outcome analyses we also linked this cohort to a number of registers on
157 demographic, socioeconomic and healthcare information; for more on these variables see S6. Data
158 was accessed on December 12th 2023.

159 Assuming an exposure of WHO's defined daily dose each day, we estimated the time varying
160 antidepressant exposure of each individual from 24 weeks before pregnancy until gestational week 36
161 in the following medication groups: selective serotonin reuptake inhibitors (SSRI; ATC codes starting

with N06AB), serotonin-norepinephrine reuptake inhibitors (SNRI; ATC codes starting with N06AX), and others antidepressants (ATC codes starting with N06AA, N06AF or N06AG). For each individual and each day, antidepressant use was classified as exposed or unexposed (0/1). A description and discussion of the tuning parameters chosen for this example may be found in S3. Seven clusters were used to describe the data.

Figure 1 characterizes the clustering of antidepressant medication patterns learned from the data using `medic()` and then illustrated with `summary()`. In the first column, the characteristics of the entire population are illustrated, and the following 7 columns display the characteristics of each cluster, highlighting distinct patterns within the data. Each row illustrates a different characteristic: number of antidepressants used per person in the cluster, frequency of use of the 5 most prevalent antidepressant ATC codes in the cluster, average cluster timing of all antidepressant medications, SSRI use, SNRI use, other antidepressant use, respectively.

For the entire study population (column 1), row 1 demonstrates that the majority (76%) of the mothers take only one antidepressant in the study period, one-fifth are exposed to two antidepressants, and even fewer (4%) are exposed to three or more antidepressants. In row 2, we see that four out of five of the most used antidepressants are SSRIs. Rows 3 to 6 show the average medication exposure trajectory among all medications (row 3), among SSRIs (row 4), among SNRIs (row 5), and among other antidepressants (row 6). As we are considering a binary exposure in this example, the average displayed may be interpreted at the percentage of pregnancies exposed at that particular timepoint. The overall average (row 3) shows that at any given week before the conception, at least half of the studied women are exposed to one or more antidepressants; then, during the 12 first weeks of pregnancy, the antidepressant use drops. This pattern is consistent across all three groups of antidepressants, but the level of use in any given week is different, with SSRI usage being consistently more frequent than SNRI and other antidepressants (rows 3-6). We further describe clusters II, III, and IV here, and all clusters in S8.

187 Cluster II – “Sustained use of one SSRI”: The second cluster, with 26% of pregnancies, is almost
188 exclusively SSRI single drug users. The pregnancies in this cluster has a high level of sustained SSRI
189 usage with at least 70% of pregnancies being exposed at any time point in the study period, and with
190 more than 90% of pregnancies being exposed in the weeks 0 to 13.

191 Cluster III – “Concomitant use of different types of antidepressants”: The third largest cluster with 13%
192 of pregnancies studied, is characterized by concomitant drug use of a mix of all 3 classes of
193 antidepressants. More than 88% of pregnancies are exposed to either SSRI or SNRI or both, while only
194 18% of pregnancies are exposed to other antidepressants. The SSRI use frequency remains fairly stable
195 across the entire exposure period, as opposed to the SNRI use frequency which drops at the start of
196 the pregnancy.

197 Cluster IV – “Multiple SSRIs used”: Cluster IV, which consists of 11% of pregnancies is characterized by
198 multiple drug use, with less than 3% using only one drug, almost 88% using 2 antidepressants, and 10%
199 using 3 or more antidepressants. Unlike cluster II, where pregnancies are exposed to a mix of different
200 types of antidepressants, in this cluster, the exposure is multiple SSRIs.

201 **Risk of redeeming psycholeptics within one year of birth according to medication cluster**
202 **membership**

203 To give an example of how to use these learned medication clusters in further analysis, we apply them
204 in an analysis of the adjusted cumulative incidence of adverse psychiatric post-partum outcomes. In
205 this example, redemption of psycholeptics (ATC group N05; anti-psychotics N05A, anxiolytics N05B,
206 and hypnotics and sedatives N05C) in the first year following birth is considered as the outcome, as it
207 serves as a concrete indicator of psychiatric distress and healthcare utilization, directly impacting
208 maternal and child well-being.

209 We used stabilised inverse probability of treatment weighting. Weight were calculated as the inverse
210 odds of being assigned medication cluster I, III, IV, V, VI or VII versus medication cluster II adjusted for

211 confounders (see S8 for the full list) in a multinomial regression model. Cluster II was chosen as the
212 reference cluster as it is a large cluster (26% or pregnancies) with a simple interpretation (sustained
213 use of one SSRI throughout the exposure period).

214 Risk ratios and risk differences were then calculated at the 365-day mark. The results of the adjusted
215 cumulative incidence analysis are shown in Figure 2a, and the estimated risk ratio and risk difference
216 by medication cluster are shown in Figure 2b.

217

218 **Figure 2.** Adjusted* risk of redeeming psycholeptics in the first year following birth according to
219 medication cluster membership.

220 (A) Adjusted cumulative incidence of redeeming psycholeptics in the first year following birth
221 according to medication cluster membership. (B) Adjusted risk ratio and risk difference per 100
222 pregnancies of redeeming psycholeptics one year after birth according to medication cluster
223 membership.

224 * Both absolute (A) and relative (B) risks were adjusted for maternal age (<25, 25-29, 30-34, ≥35), parity
225 (0, 1, 2, ≥3), BMI (<18.5, 18.5-25, 25-30, 30-35, >35), smoking status (non-smoker, stopped smoking
226 or smoker), family structure (married, single, or living with partner), maternal employment status
227 (employed, employed in a management position, self-employed, or unemployed and receiving public
228 assistance), maternal level of education (primary, secondary, postsecondary, or vocational school),
229 location of residence in Denmark (capital region, central region, northern region, Zealand, or southern
230 region), disposable household income (quartile 1, 2, 3, or 4), and maternal country of origin (Denmark,
231 Europe (without Denmark), or other), history of psychiatric hospitalizations, history of self-harm and
232 Charlson comordibity score ≥1.

233

234 From Figure 2b we see that three clusters have a significantly reduced risk of redeeming psycholeptic
235 prescriptions within 1 year of birth as compared with cluster II, sustained exposure to one SSRI. These
236 three clusters are cluster I ("discontinuation of SSRI's"), cluster V ("discontinuation of SNRI's") and
237 cluster VI ("single use of antidepressants in the other antidepressants group"). Conversely, cluster III
238 ("multiple medication used across antidepressant groups") is significantly associated with an increased
239 risk of redeeming psycholeptics within 1 year of birth as compared with cluster II ("sustained use of on
240 SSRI").

241 We can also observe from Figure 2b that neither cluster IV ("multiple SSRI's used"), nor cluster VII
242 ("sustained use of SNRI or other-antidepressants") where significantly associated with a higher risk of
243 redeeming psycholeptics as compared with cluster II ("sustained use of on SSRI"). All statistical
244 conclusions were supported on both the risk ratio and risk difference scale.

245 DISCUSSION

246 The `tame` package implements a novel data-driven learning method for understanding individual-level
247 medication patterns through hierarchical clustering and provides tools for illustrating and
248 characterising these clusters. The method utilises the anatomical, therapeutic and chemical
249 classifications of the drug, the exposure timing, and dose intensity together to define similarities
250 between personal medication patterns. In addition, the method allows for tuning to a range of contexts
251 and research questions. Moreover, a method for applying existing medication clusters to new
252 medication pattern data has been developed.

253 Here, we demonstrated how `tame` can help identify and narrow down complex trends of
254 antidepressant use before- and during pregnancy, using a national Danish cohort. In general, clustering
255 real-world medication data offers a valuable automated search method for detecting potential safety
256 signals or adverse drug interactions that may not have been previously suspected. Unlike traditional
257 approaches that rely on specific suspicions or hypotheses, clustering allows for an exploratory analysis

258 of medication patterns. For example, through clustering, researchers may discover that a particular
259 cluster, such as medications X and Y frequently taken together, is associated with an elevated risk of
260 adverse outcomes. This automated identification of medications and medication combinations that
261 pose potential risks can serve as an early warning system, prompting further investigation into these
262 specific medication combinations and their effects.

263 Moreover, real-world medication patterns captured through clustering analysis reflect the diverse
264 medication usage habits of individuals outside controlled clinical trial settings. This real-world
265 complexity adds depth to our understanding of medication usage and its implications. Additionally,
266 these patterns can be leveraged for statistical adjustment or stratification in epidemiological studies.
267 By accounting for these real-world medication patterns, researchers can better control for
268 confounding factors and obtain more accurate estimates of treatment effects in epidemiological
269 studies and observational research.

270 When using this method, specifying tuning parameters provides great customizability but require
271 decisions from the researcher. Thus, tuning the distance measure will still have to be done in
272 accordance with the understanding of the studied medication and the clinical setting. However,
273 methods for algorithmically optimizing the number of clusters and assisting in the choice of linkage
274 according to measures of goodness of fit is currently underway.

275 Naturally, clustering personal medication usage according to ATC codes is limited by the ATC
276 classification system itself. The ATC hierarchy classify according to main therapeutic use or mechanism
277 of action of the main active ingredient, and as such, encode the main indication of the drug. Many
278 medications are used for multiple indications but will only be assigned one ATC code according to the
279 main indication. Moreover, an ATC group may be specified according to mechanism of action, resulting
280 in groups where the medications have many different indications. In addition, a chemical substance
281 may be given more than one ATC code if it is used for two different therapeutic purposes. For a
282 detailed introduction to the construction of WHO's ATC classification system see (11). Thus, as the ATC

classification system classifies both according to the therapeutic and the pharmacological aspects of a medication, so does the classification method presented in this paper. Methods for extending the ATC distance measure to allow for user defined exceptions or additions to the ATC classification system are in progress. This extension will allow the user to give all medications with identical active ingredients a smaller distance regardless of distance in the ATC hierarchy or make combination products more similar than the ATC hierarchy suggests.

In addition, a central feature of hierarchical clustering, and many other clustering methods, is that all observations are assigned a cluster. Thus, if the data contain many outliers, which in fact are not comparable with other observation in the data, these will still be placed in clusters. Moreover, the assignment to a cluster is done in a deterministic way, and the method does not provide uncertainty estimates for this assignment. These features of clustering lead to less robustness to changes to the study population. When using `tame`, the `employ()` function can be used to gain some insight into the extent of this problem in a given dataset through cross validation type strategies.

Lastly, it should be noted that clustering methods can be very computationally time and RAM demanding. This means that we may still be limited in our applications of this method to large cohorts with wide medication use by our computational power. As discussed in S4, this central limitation has informed multiple design aspects of the code itself, and computationally intensive parts of the code are written in C++ or utilize code written in Fortran. This works to ensure a relatively respectable computational time for our example with just over 33,000 antidepressant exposed pregnancies of less than 10 minutes on a system with Intel(R) Xeon(R) Gold 6254 CPU @ 3.10GHz.

Conclusions

In summary, the `tame` package improves on classical approaches to understanding drug exposure by clustering complex, real-world use patterns which integrate information on timing, dose, and type of medication. Here, we described an application of how we have used this method to understand antidepressant use up to and during pregnancy, and then analyse how these learned clusters were

associated with the use of psycholeptics in the first year following birth. In the future, the method may be used to understand other patterns of prescription drug use and optimize drug safety surveillance through data driven learning.

ACKNOWLEDGMENT

Authors thank Kim Daniel Jakobsen for his invaluable assistance in the development of the methodology employed in this study. We would also like to thank Elisabeth O'Regan for her meticulous attention to detail in formatting and refining the English language of this manuscript.

AUTHOR CONTRIBUTIONS

Conceptualising R package functionalities: A.D.L. and J.W. Code development and documentation: A.D.L. Code testing: A.D.L. Study concept and design: A.D.L., J.W. and A.H.. Data analysis: A.D.L. Manuscript writing: A.D.L. Critical review: A.D.L., A.H. and J.W. Funding: A.H.

FUNDING

This work was supported by a grant from the Independent Research Fund Denmark – "Exploring new ways of classifying medication use in pregnancy for better observational research" (9039-00055B)

CONFLICT OF INTEREST

We declare no conflicts of interest.

REFERENCES

1. Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, et al. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women? *Pharmacoepidemiology and Drug Safety*. 2016; 25(7): 770-777.

2. Wood ME, Lupattelli A, Palmsten K, Bandoli G, Hurault-Delarue C, Damase-Michel C, et al. Longitudinal Methods for Modeling Exposures in Pharmacoepidemiologic Studies in Pregnancy. *Epidemiologic Reviews*. 2021; 43(1): 130-146.

3. Lemon LS, Bodnar LM, Garrard W, Venkataramanan R, Platt RW, Marroquin OC, et al. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. *International Journal of Epidemiology*. 2019; 49(2): 648-656.

4. Steinley D. K-means clustering: A half-century synthesis. *British Journal of Mathematical and Statistical Psychology*. 2006; 59(1): 1-34.

5. Genolini C, Alacoque X, Sentenac M, Arnaud C. kml and kml3d: R Packages to Cluster Longitudinal Data. *Journal of Statistical Software*. 2015; 65(4): 1-34.

6. Genolini C, Falissard B, Kiener P. R package version 2.4.6. [Online].; 2023. Available from: https://CRAN.R-project.org/package=kml.

7. Proust-Lima C, Philipps V, Liquet B. Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: The R Package lcmm. *Journal of Statistical Software*. 2017; 78(2): 1–56.

8. Salvatore S, Domanska D, Wood M, Nordeng H, Geir Kjetil S. Complex patterns of concomitant medication use: A study among Norwegian women using paracetamol during pregnancy. *PLOS ONE*. 2017; 12(12): 1-11.

9. Laksafoss A. tame: Timing, Anatomical, Therapeutic and Chemical Based Medication Clustering. 2023-02-23 Feb 23. R package version 0.0.1. https://CRAN.R-project.org/package=tame.

10. Bliddal M, Broe A, Pottegård A, Olsen J, Langhoff-Roos J. The Danish Medical Birth Register. *European Journal of Epidemiology*. 2018 January; 33(1): 27-36.

11. Health, Norwegian Institute of Public. WHO collaborating Center for Drug Statistics Methodology. [Online].; Last updated: 2022-11-10 [cited 2023-12-19]. Available from: https://www.whocc.no/atc/structure_and_principles/.

12. Trinh NTH, Munk-Olsen T, Wray NR, Bergink V, Nordeng HME, Lupattelli A, et al. Timing of Antidepressant Discontinuation During Pregnancy and Postpartum Psychiatric Outcomes in Denmark and Norway. *JAMA Psychiatry*. Published online March 08, 2023.

13. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data Resource Profile: The Danish National Prescription Registry. *International Journal of Epidemiology*. 2017; 46(3): 798-798f.

14. Bliddal M, Broe A, Pottegård A, Olsen J, Langhoff-Roos J. The Danish Medical Birth Register. *European Journal of Epidemiology*. 2018 January; 33(1): 27-36.


Population (n = 33655)
I (n = 11272)
II (n = 8586)
III (n = 4418)
IV (n = 3563)
V (n = 3241)
VI (n = 1324)
VII (n = 1251)
Medication Amount
ATC Frequency
Average Trajectory
SSRI
SNRI
Other Anti-depressants
27329 (81%)
11256 (100%)
8586 (100%)
3904 (88%)
3563 (100%)
8 (0%)
<5
9 (1%)
8308 (25%)
<5
6 (0%)
3922 (89%)
84 (2%)
3239 (100%)
5 (0%)
1048 (84%)
2423 (7%)
28 (0%)
806 (18%)
43 (1%)
8 (0%)
1324 (100%)
213 (17%)
Weeks (24 weeks before pregnancy until week 36 of pregnancy)
Medication Amount
1
2
3
4+
ATC codes
N06AB03
N06AB04
N06AB05
N06AB06
N06AB10
N06AX03
N06AX11
N06AX12
N06AX16
N06AX21
N06AA02
N06AA04
N06AA09
N06AA10
Remaining
ATC group specific trajectories
SSRI
SNRI
Other Anti-depressants

Figure 1

A



B

Cluster		Number of pregnancies	Risk Ratio (95% Conf. Int.)	Risk Difference per 100 pregnancies (95% Conf. Int.)
Cluster I	"Discontinuation of SSRI's"	11,272	0.83 (0.76 – 0.90)	−2.26 (−3.27 – −1.25)
Cluster II	"Sustained use of one SSRI"	8,586	1 (Ref)	0 (Ref)
Cluster III	"Multiple medication used across anti−depressant groups"	4,418	1.31 (1.18 – 1.43)	3.98 (2.53 – 5.43)
Cluster IV	"Multiple SSRI's used"	3,563	1.08 (0.96 – 1.19)	1.03 (−0.45 – 2.50)
Cluster V	"Discontinuation of SNRI's"	3,241	0.75 (0.65 – 0.84)	−3.27 (−4.60 – −1.93)
Cluster VI	"Single use of antidepressants in the other anti−depressants group"	1,324	0.81 (0.64 – 0.97)	−2.54 (−4.78 – −0.29)
Cluster VII	"Sustained use of SNRI or other−antidepressants"	1,251	1.17 (0.91 – 1.42)	2.17 (−1.14 – 5.49)

Figure 2